ContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference
February 09 2018 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today that it will present
at BIO CEO & Investor Conference 2018, to be held February
12-13, 2018, at the Marriott Marquis in New York.
James Sapirstein, Chief Executive Officer of
ContraVir, will provide an overview of the company's business and
will be available to participate in one-on-one meetings with
investors who are registered to attend the conferences.
Presentation Date: Monday,
February 12thPresentation Time: 10:00AM (Eastern
Time)Presentation Room:
ZiegfeldLocation: Marriott Marquis
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development
and commercialization of targeted antiviral therapies with a
specific focus on developing a potentially curative therapy for
hepatitis B virus (HBV). The company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™,
designed to deliver high intrahepatic concentrations of TFV while
minimizing off-target effects caused by high levels of circulating
TFV, recently completed a Phase 2a trial. CRV431, the other
anti-HBV compound, is a next-generation cyclophilin inhibitor with
a unique structure that increases its potency and selective index
against HBV. In vitro and in vivo studies have thus far
demonstrated that CRV431 reduces HBV DNA and other viral proteins,
including surface antigen (HBsAg). For more information
visit www.contravir.com.
For further information, please
contact: Sharen Pyatetskaya Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Jul 2023 to Jul 2024